Ethan Lipkind - Complete Healthcare Management Releases Study on ViiV Healthcare's Dolutegravir Patent

Copy Link

CHM has actually championed and supported improved access to health care and lowered costs with a specific concentrate on those most susceptible. CHM developed a non-profit rural health system to help make sure ongoing gain access to for healthcare to tens of thousands of patients, and, more just recently, helped establish a Medicare Advantage strategy which cares for a disproportionately underserved population. Now, CHM is concentrated on drug store spend. CHM thinks it can help to manage runaway pharmaceutical expenses by attempting to shed light on those patents supporting very expensive drugs which might be overly broad or have been artificially extended beyond their original lifetimes. Among the avenues that they have actually picked to follow is to provide their findings to the public, either through the filing of public court documents or by releasing the data straight to other interested 3rd parties, in order to assist get rid of flawed patents.

IPR has actually established an extensive and multifaceted process for identifying pharmaceutical patent filings that have made the most of the patent system. The main patent for dolutegravir was submitted in April of 2006 and is based upon innovation focused around inhibition of HIV integrase, an enzyme essential for HIV infections. According to Dr. R.L. Smith of IPR, "" At the time of the filing, dozens of compounds were understood that prevented HIV integrase. Not only were a number of HIV integrase inhibitors already developed, however many also had the very same or similar structural elements as ViiV'' s dolutegravir. We think that the substance that was eventually authorized as dolutegravir was in fact currently apparent in the prior art when the '' 385 was submitted. We have actually presented our best arguments in this report."

" CHM President ethan lipkind said, "" We hope that other pharmaceutical companies or interested celebrations will be able to leverage this information to perhaps produce cheaper generic versions of this drug and to bring down the general cost of HIV treatment for our consumers and clients."